m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT02097
 [1]
m6A modification Circ_YTHDC2 Circ_YTHDC2 YTHDC2 : m6A sites Indirect Inhibition DNA methylation TET2 Regulated Target
m6A Modification:
m6A Regulator YTH domain-containing protein 2 (YTHDC2) READER
 Regulator Info 
m6A Target Circ_YTHDC2
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type DNA methylation (DNAMeth)
Epigenetic Regulator Methylcytosine dioxygenase TET2 (TET2) ERASER View Details
Crosstalk Relationship m6A  →  DNA methylation Inhibition
Crosstalk Mechanism m6A modification indirectly regulates DNA methylation through downstream signaling pathways
Crosstalk Summary YTHDC2-Mediated Circ_YTHDC2 N6-Methyladenosine Modification Promotes Vascular Smooth Muscle Cells Dysfunction Through Inhibiting TET2.
Responsed Disease Hematological disorders ICD-11: 3C0Z
 Disease Info 
Cell Process Cell proliferation
Cell migration
In-vitro Model
 A7r5 Normal Rattus norvegicus CVCL_0137
In-vivo Model Sprague Dawley rats were anesthetized by intraperitoneal injection of 1.5% pentobarbital sodium at 0.2 mL/100 g. The thoracic aorta was separated under aseptic conditions, and was placed in pre-cooled DMEM medium, and the tunica media was separated under a microscope. The tunica media were cut into small pieces of 0.5-1 mm2, and digested with type II collagenase (2 mg/mL) in a 37°C water bath. The cells were collected by centrifugation, and resuspended in DMEM medium containing 20% FBS. The collected cells were planted in a 6 cm polylysine-coated culture dish, and were cultured in cell incubator for 48 h. The cells were sub-cultured in DMEM medium containing 10% FBS after fusion to 80%. For primary VSMCs stimulated by high glucose, 25 mmol/L glucose (high glucose group) was added and cultured for 24 h for subsequent experiments. primary VSMCs cultured with 5 mmol/L glucose were used as a negative control.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
3C0Z: Hematological disorders 5 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Lmw heparin Approved [2]
Synonyms
Fragmin; Heparinin; MolPort-042-652-620; Logiparin (TN); Sandoparin (TN)
    Click to Show/Hide
External Link
CID: 25244225
TTD: D08PSU
 Compound Name CK0801 Phase 1 [3]
External Link
TTD: DX8QZ3
 Compound Name HemoTech Investigative [4]
Synonyms
Blood substitute (hematological disease), HemoBiotech; Bovine hemoglobin + adenosine 5'-triphosphate + o-adenosine + reduced glutathione (hemotological disease), HemoBiotech
    Click to Show/Hide
External Link
TTD: D0BA8H
 Compound Name PN-951 Investigative [4]
External Link
TTD: D06WLY
 Compound Name Hematological disease agents Investigative [4]
Synonyms
Hematological disease agents, Tartis; SM-27
    Click to Show/Hide
External Link
CID: 486047
TTD: D03BPU
References
Ref 1 YTHDC2-Mediated circYTHDC2 N6-Methyladenosine Modification Promotes Vascular Smooth Muscle Cells Dysfunction Through Inhibiting Ten-Eleven Translocation 2. Front Cardiovasc Med. 2021 Oct 1;8:686293. doi: 10.3389/fcvm.2021.686293. eCollection 2021.
Ref 2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 3 ClinicalTrials.gov (NCT03773393) A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF). U.S. National Institutes of Health.
Ref 4 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.